Future studies should prioritize standardized core outcome sets, with MRI-PDFF as the preferred non-invasive measure of hepatic steatosis and liver stiffness measurement by elastography for fibrosis assessment, to enhance cross-trial comparability and facilitate meta-analysis (83, 88)
Future studies should measure multiple nutrients simultaneously and use multivariate models to isolate the independent effects of individual nutrients
Other Rare Side Effects: Pancreatitis and gallbladder issues are uncommon but severe
The intraretinal fluid extended slightly into the macula with the fluid margin 2.4 mm from fovea centralis corresponding to within the ETDRS grid (scan including ETDRS grid was not obtained)
Novo Nordisks Wegovy (semaglutide), the first and only once-weekly GLP-1 receptor agonist approved for weight management in people with obesity, has been found to help patients lose up to 15 percent of their body weight in over 68 weeks
Zepbound is a brand-name tirzepatide medication that may be considered for chronic weight management in eligible patients when clinically appropriate
